Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of molecular and cellular cardiology"
DOI: 10.1016/j.yjmcc.2022.03.003
Abstract: RATIONALE Mineralocorticoid receptor (MR) antagonists have been clinically used to treat heart failure. However, the underlying cellular and molecular mechanisms remain incompletely understood. METHODS AND RESULTS Using osteoblast MR knockout (MRobko) mouse in combination with… read more here.
Keywords: ventricular remodeling; deficiency; myocardial infarction; osteoblast deficiency ... See more keywords